In standard drug trials comparing antidepressants with placebo, a peri
od of typically 3 weeks is required before formal statistical signific
ance between treatments is achieved. This delay has often been interpr
eted as indicating a delayed onset of action of antidepressants. Howev
er, detailed analyses of the time course of recovery from depression d
emonstrate that the 'delayed onset' hypothesis needs revision. The res
pective findings, now replicated across several differing antidepressa
nt drug classes and placebo, suggest that: (i) among responders, the o
nset of improvement occurs in more than 70% of cases within the first
3 weeks of treatment; (ii) there is no evidence of a pronounced increa
se in improvement rates beyond this time point; and (iii) early improv
ement is highly predictive of better later outcome. Most notably, the
time course of improvement appears to be independent of the treatment
modality, and effective antidepressants seem to merely trigger and mai
ntain the conditions necessary for improvement, irrespective of their
primary site of action within the monoaminergic systems. Differences b
etween the efficacy of active drugs and placebo are reflected both by
the total number of patients who improve, and by the number and time d
istribution of patients who withdraw prematurely. As a consequence, th
e therapeutic qualities of antidepressants may not lie in their suppre
ssion of symptoms, but rather in their ability to convert a percentage
of 'nonresponders' to 'responders', triggering and maintaining the co
nditions necessary for improvement in the early stages of treatment. C
learly, all these findings, which are at odds with the 'delayed onset'
hypothesis, require further study to detail the extent to which antid
epressants act nonspecifically by 'kick starting' a remission in the e
arly stages of treatment. In addition, the characteristics that distin
guish 'true' drug responders from placebo responders remain to be clar
ified.